相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1823
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The American Heart Association has appointed Bradley A. Maron, M.D., FAHA, as the new editor-in-chief of Circulation, effective July 6, 2026. - Dr. Maron is a clinical cardiologist and globally recognized researcher in pulmonary hypertension, right heart failure, and precision medicine at the University of Maryland. - The journal will introduce new features including Clinician Lighthouse articles, graphic abstracts for all research papers, and a Patient's Corner for public engagement. - Maron succeeds Joseph A. Hill, M.D., who led Circulation since 2016, and brings over 260 scientific publications and six patents to the role.
- Nature Cell has revived development of Vascostem, an autologous adipose-derived stem cell therapy for Critical Limb Ischemia, targeting FDA approval by 2030 through RMAT designation. - Clinical trials demonstrated complete prevention of major amputation in 15 patients at 6-month follow-up, with only 33.3% requiring minor amputation procedures. - The company has secured advisory support from 2019 Nobel Prize winner Professor Gregg Semenza to optimize treatment approaches and strengthen regulatory strategy. - Vascostem CLI will be manufactured at a Baltimore GMP facility with an anticipated treatment price exceeding $50,000 upon U.S. commercialization.
- Massachusetts General Hospital successfully performed its second pig-to-human kidney transplant using Eledon's tegoprubart as a key immunosuppressant, with the patient now off dialysis after two years. - Tegoprubart, an anti-CD40L antibody, demonstrates potential in preventing organ rejection by blocking multiple costimulatory receptors, marking a significant advancement in xenotransplantation. - The procedure, performed on January 25, 2025, represents a crucial milestone in addressing the global organ shortage crisis, with MGH planning two additional xenotransplants this year.
- A pooled analysis of Phase III clinical trials reveals that cognitive side effects following cranial radiation therapy for brain metastases may be fully reversible. - Conformal radiation techniques, such as stereotactic radiosurgery (SRS) and hippocampal avoidance WBRT, are more likely to result in cognitive recovery compared to whole-brain radiation therapy (WBRT). - Six months after cognitive decline, 38% of patients experienced full cognitive recovery, increasing to 42% at one year, with even more showing some cognitive improvement. - The findings suggest that cognitive dysfunction should not be viewed as a permanent endpoint, offering hope for improved long-term quality of life for patients with brain metastases.
